anti-SSTR2/CD3 monoclonal antibody XmAb18087
Term · Oncology and biomedicine · MLC-T-ONC-011099
A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, anti-SSTR2/CD3 monoclonal antibody XmAb18087 binds to both T cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.
| Identifier | MLC-T-ONC-011099 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-SSTR2 x anti-CD3 monoclonal antibody XmAb18087 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011099",
"term": "anti-SSTR2/CD3 monoclonal antibody XmAb18087",
"field": "Oncology and biomedicine",
"definition": "A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, anti-SSTR2/CD3 monoclonal antibody XmAb18087 binds to both T cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.",
"synonyms": [
"anti-SSTR2 x anti-CD3 monoclonal antibody XmAb18087"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-sstr2-cd3-monoclonal-antibody-xmab18087/"
}
Record 2,242 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.